外泌体PD-L1水平越高,T细胞难以通过抗PD-1治疗再活化。 治疗中:外泌体PD-L1增加与T细胞再活化有关,可以反映抗PD-1疗法引发的成功的抗肿瘤免疫。虽然外泌体PDL1响应于IFN-γ的升高可以使肿瘤细胞适应性地灭活CD8 T细胞,但这是徒劳的,因为PD-L1 / PD-1相互作用被佩布利珠单抗阻断。对于无反应者,不能观察到...
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarify predictive biomarkers for drug efficacy ...
Recently, a series of studies reported that IFN-纬 can stimulate cancer cells to release exosomal PD-L1 (exoPD-L1), which possesses the ability to suppress anticancer immune responses and is associated with anti-PD-1 response. In this review, we introduce the PD-1...
In this study, we obtained high concentration of PD-L1 in exosomes from either genetically engineered cells overexpressing PD-L1 or IFN-纬 stimulated cells. We found that exosomal PD-L1 is specially bound to PD-1 on T cell surface, and suppressed T cell activation. Interestingly, exosomal PD...
In addition to increasing the expression of programmed death-ligand 1 (PD-L1), tumor cells can also secrete exosomal PD-L1 to suppress T cell activity. Emerging evidence has revealed that exosomal PD-L1 resists immune checkpoint blockade, and may contrib
Exosomal PD-L1 suppresses T cell effector function, induces systemic immunosuppression, and transfers functional PD-L1 across the tumor microenvironment (TME). Because of its significant contribution to immune escape, exosomal PD-L1 has been proposed as a biomarker to predict im...
外泌体 PD-L1 有助于免疫抑制并与抗 PD-1 反应相关 肿瘤细胞通过上调程序性死亡配体 1 (PD-L1) 的表面表达来逃避免疫监视,该配体与 T 细胞上的程序性死亡 1 (PD-1) 受体相互作用,引发免疫检查点反应 1,2。抗 PD-1 抗体在治疗肿瘤(包括转移性黑色素瘤)方面显示出非凡的前景2-4。然而,患者的反应率...
Removal of exosomal PD-L1 inhibits tumor growth, even in models resistant to anti-PD-L1 antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph node. Systemically introduced exosomal PD-L1 rescues growth of tumors unable to secrete their own. Exposure to ...
Exosomal PD-L1CD28immune checkpoint inhibitorresponse predictionanti-PD1 therapyBackground: Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues affdoi:10.2139/ssrn.3514597Zhang, Chaoxu...
Programmed cell death ligand 1 (PD‐L1) is an immune surface protein that binds to programmed cell death 1 (PD‐1) and allows tumors to evade T‐cell immunity. This study aims to define the role of PD‐L1 shuttled by tumor cell‐derived exosomes in the immune escape of nasopharyngeal ca...